Dulal S, Paudel BD, Neupane P, et al. - In this randomized, phase II trial, researchers compared olanzapine (OLN; a higher-cost drug) vs haloperidol (HAL; a lower-cost drug) in terms of efficacy and toxicity when administered as a prophylactic against the development of chemotherapy-induced nausea and vomiting (CINV) in patients who were treated with highly emetogenic chemotherapy (HEC). They randomly allocated the participants to receive either OLN 10 mg orally on days 1 to 4 or HAL 1 mg orally on day 1 and 0.5 mg twice daily on days 2 to 4. Ondansetron 16 mg and dexamethasone 12 mg intravenously on day 1 were administered to both groups. Complete nausea prevention (Edmonton Symptom Assessment Scale of 0) was considered as the primary endpoint, and complete emesis prevention was regarded as secondary endpoint. As for toxicities, no difference was seen between treatment arms. Findings revealed that efficacy displayed by HAL was comparable to that of OLN for the management of CINV, indicating it as the higher-value choice in patients who take HEC in resource-scarce countries.